PPARG and metabolic syndrome: As PPARγ is a significant drug target for metabolic syndrome associated with obesity-induced insulin resistance and hyperglycemia31, 32, we used the db/db diabetic mouse model and their littermates to determine whether chelerythrine has the ability to improve glucose homeostasis in these mice.